Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Neoplasms 2Endometrial Neoplasms 2Breast Neoplasms 2Wilms Tumor 1Vulvar Neoplasms 1Vaginal Neoplasms 1Urinary Bladder Neoplasms 1Tongue Neoplasms 1Thyroid Cancer, Papillary 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Salivary Gland Neoplasms 1Recurrence 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pheochromocytoma 1Penile Neoplasms 1Parathyroid Neoplasms 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Mycosis Fungoides 1Mouth Neoplasms 1

Interventions

Carboplatin 19Paclitaxel 17Cisplatin 9Cyclophosphamide 8Gemcitabine 7Bevacizumab 6Topotecan 5pembrolizumab 4olaparib 4liposomal doxorubicin 4durvalumab 4Letrozole 4Interleukin-2 4Drug Therapy 4Doxorubicin 4Albumin-Bound Paclitaxel 4rucaparib 3fludarabine 3chiauranib 3cemiplimab 3camrelizumab 3Therapeutics 3Itraconazole 3Injections 3Hyperthermic Intraperitoneal Chemotherapy 3Everolimus 3pazopanib 2iniparib 2eprenetapopt 2avelumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Ritonavir × Gynecologic × Clear all
NCT05150691 2026-01-28

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

DualityBio Inc.

Phase 1/2 Recruiting
796 enrolled
BreastGastrointestinalGynecologicThoracic

Bile Duct Neoplasms, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡